GNPX saw a ton of attention yesterday on the heels of major FDA related news.

StockWireNews

Your Friday Nasdaq Profile (GNPX) Update

Two Major Targets From Alliance Global Partners ($8.00) And Noble Financial ($5.00) Provide Major Upside Potential

Find The Price Targets Here

October 30th

Good Morning,

GNPX saw a ton of attention yesterday on the heels of major FDA related news.

Opening at $3.17, GNPX ran to a high of $3.58 for an approximate run of 12.9% intraday.

Overall, hitting that $3.58 day high yesterday put GNPX up approximately 15.8% from Wednesday's close.

In case you missed it, here's the news that became yesterday's major catalyst: Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Check out the full article here.

When the market finally closed yesterday, GNPX saw a boost on Barchart from an "8% BUY" after Wednesday's close to a "40% BUY" based on overall technical indicators.

GNPX also saw a bounce from levels near its 200-Day Simple Moving Average up towards its 13-Day Exponential Moving Average which it battled most of the day.

With its 50-Day SMA in striking distance, a potential breakout squeeze could be looming if it can push past that line of resistance in the near term.

If you haven't yet, read my full initial GNPX report below and get it on your radar now.

-----

There's no time to waste this morning as your new NASDAQ profile Genprex, Inc. (GNPX) could be breakout bound.

Back on February 11th, I brought GNPX to your attention at approximately $1.61 and watched it run to a February 25th high of $7.03 for an approximate 336% move.

Then, I followed up with GNPX when I brought it to your attention on July 22nd and watched it run from an open of $3.45 to July 23rd's high of $4.50 for a two day surge of approximately 30%.

Genprex, Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes.

Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options.

And, several key driver indicators could be signaling an upcoming vertical move for GNPX. Read on...

Could A Recent Downtrend Signal An Upcoming Reversal?

Here's Investopedia's definition of a reversal:

A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart.

Now, I want you to take a look at GNPX's 3-month chart:

image

As you can see, GNPX has been in a recent downtrend since mid October. Here's why that could all change soon.

No. 1 Potential GNPX Driver Indicator

Right now, according to Barchart, GNPX is displaying several oversold leaning technical indicators. Here's a sample:

  • 9-Day Relative Strength Index = 30.24%
  • 14-Day Relative Strength Index = 36.02%

When those two figures hit the low 30% range and delve into the upper 20% range, traders can view a profile as oversold, leading them to believe it is undervalued.

  • 14-Day Raw Stochastic = 20.66%
  • 14-Day Williams %R = 79.34%

When the Raw Stochastic nears single digits and the Williams %R nears the 90% level, traders can also view a profile as oversold and undervalued.

On top of all those oversold leaning technicals, Barchart is also reporting several technicals to be triggered as bullish. They are GNPX's:

Short Term Indicators

  • 20 - 100 Day MACD Oscillator
  • 20 - 200 Day MACD Oscillator

Medium Term Indicators

  • 50 - 100 Day MACD Oscillator
  • 50 - 150 Day MACD Oscillator
  • 50 - 200 Day MACD Oscillator

Long Term Indicators

  • 200 Day Moving Average
  • 100 - 200 Day MACD Oscillator

It's an interesting mix of technicals, both bullish and oversold. Keep an eye on these closely as they may signal GNPX's next breakout if more become triggered.

-----

No. 2 Potential GNPX Driver Indicator

James Molloy of Alliance Global Partners issued a new price target on April 22nd of 2020.

At the time, the stock was trading at $1.99. He initiated coverage and provided an $8.00 price target.

As of Wednesday's closing valuation of $3.09, GNPX is now displaying upside potential of 158% to that target.

Remember, it was just a few months back that we saw GNPX climb over the $7.00+ level when I brought it to your attention in February.

Could this stock's next big run be right around the corner?

Additionally, another analyst, Cosme Ordonez from Noble Financial has also pegged GNPX with a $5.00 target.

From Wednesday's close of $3.09, that provides GNPX with upside potential of 61%.

Now, I'm not saying that GNPX is going to be running to either of those targets today, but you need to be aware of the potential upside for this profile.

-----

No. 3 Potential GNPX Driver Indicator

Genprex Added to Russell 3000® Index

Read the full article here.

Here's Why This News Could Change Everything

When an emerging growth company like GNPX joins the Russell 3000® Index, this can be a game-changing event that transforms a stock.

GNPX will now have an increased ability to attract institutional buying from hedge funds, banks, mutual funds, and 401 (k)'s.

-----

No. 4 Potential GNPX Driver Indicator

National Institutes of Health (NIH) Awards Research Grant of $2.59Mn to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex

Read the full article here.

-----

No. 5 Potential GNPX Driver Indicator

According to Yahoo Finance, GNPX currently has an approximate 31.73Mn shares in its float.

As we've seen in previous stock profiles, including this one when I brought it to you back in February (approximately 336% surge in roughly two weeks) and July (approximately 30% in 2 days), a low float can lead to explosive vertical surges in the short-term from volatility.

Biotech stocks can be very sensitive to news. One major development -- such as a positive result from a clinical trial -- and share prices can take off in a hurry.

Could the next big news coming from the GNPX camp be the spark to send share prices vertical?

-----

More About The Company: Genprex, Inc.

From the company website:

Our mission is to develop life-changing gene therapies for patients with cancer and diabetes through unique, innovative science.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases.

The company’s lead product candidate is GPX-001 (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC). The active ingredient in GPX-001 is the TUSC2 gene, a tumor suppressor gene. GPX-001 uses the company’s unique, proprietary Oncoprex™ nanoparticle delivery platform which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for GPX-001 in combination with AstraZeneca’s Tagrisso® for the treatment of NSCLC. GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies.

-----

If there are any more updates today, I'll get them out to you quickly.

Sincerely,

Kai Parker

StockWireNews


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Stock Wire News (stock wire news . com) is owned by Stock News Wire LLC, a limited liability company. A member of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierce investor . com (“FI”), an interest in the limited liability company that owns and operates stock street wire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, Stock Wire News, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockWireNews LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 1/21/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockWireNews LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 2/11/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid forty-six thousand USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockWireNews LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 5/5/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockWireNews LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 6/4/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twelve thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockWireNews LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 7/22/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockWireNews LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 10/29/20 and ending on 10/30/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid thirty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). To date, we have now been compensated a total of one hundred seventy-three thousand five hundred USD to disseminate information about (GNPX).